CT:LMNL Liminal BioSciences Inc.
Liminal BioSciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs. It operates through three segments: Small Molecule Therapeutics, Plasma Derived Therapeutics, and Bioseparations. The Small Molecule Therapeutics segment's lead product candidate is PBI-4050, which targets unmet medical needs, such as the treatment of idiopathic pulmonary fibrosis, Alström syndrome, and other fibrotic indications. The Plasma Derived Therapeutics segment provides Plasma Protein Purification System, a multi-product sequential purification process for the extraction and purification of therapeutic proteins from human plasma. It also engages in developing Ryplazim for the treatment of congenital plasminogen deficiency. The Bioseparations segment develops and manufactures affinity absorbents and Mimetic Ligand purification platform that are used by pharmaceutical and medical companies for extraction and purification manufacturing processes. In addition, it develops processes to recover and purify various other proteins from plasma, including intravenous immunoglobulin, inter-alpha-inhibitor-proteins, fibrinogen, alpha1 antitrypsin, and C1 esterase inhibitor. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.
This company cross-lists their shares on a U.S. stock exchange. See the related U.S. symbol LMNL.
This company has cross-listed shares that trade in the U.S. as the symbol LMNL.
22.84 CAD
As of 08/05/2020
Security Information
Category1: Global Equity
Category2: Common stocks
Category3: Developed markets ex-US
GICS sector: Health Care
Industry: Biotechnology
Index country: Canada
Country of incorporation: Canada
IPO date: 01/01/1900
Stock exchange: Toronto Stock Exchange
Exchange country: Canada
Market cap: 539,542,464 CAD
Current dividend yield: 0.00%
Sedol: